Accueil   Diary - News   All news Adocia announces receipt of USD 14.3B payment and the decision by mutual consent with Eli Lilly to conclude the civil case

Adocia announces receipt of USD 14.3B payment and the decision by mutual consent with Eli Lilly to conclude the civil case

 

Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case


• The payment of USD 14.3 million corresponds to the USD 11.6 million in damages plus interest awarded to Adocia in August 2018 by an American Arbitration Association Panel presiding over Adocia’s arbitration claims against Eli Lilly
• Independently, Adocia and Eli Lilly together agreed to file a consent judgment to conclude the civil litigation initiated by Eli Lilly at the Court of the Southern District of Indiana


Lyon, France, September 30, 2019 – 7:30 am CEST - Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, today announced that it received a USD 14.3 million payment, or EUR 13.0 million, from Eli Lilly & Company (“Lilly”).

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree